Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other financing activities (2016 - 2024)

Lifecore Biomedical, Inc. \De\ (LFCR) has 14 years of Other financing activities data on record, last reported at $107000.0 in Q2 2024.

  • For Q2 2024, Other financing activities fell 95.51% year-over-year to $107000.0; the TTM value through May 2025 reached $6.2 million, changed 0.0%, while the annual FY2025 figure was $435000.0, 88.31% up from the prior year.
  • Other financing activities reached $107000.0 in Q2 2024 per LFCR's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $8.4 million in Q1 2021 and bottomed at $37000.0 in Q1 2022.
  • Average Other financing activities over 5 years is $1.7 million, with a median of $725000.0 recorded in 2020.
  • Peak YoY movement for Other financing activities: plummeted 99.56% in 2022, then skyrocketed 9816.22% in 2023.
  • A 5-year view of Other financing activities shows it stood at $725000.0 in 2020, then tumbled by 81.79% to $132000.0 in 2021, then surged by 393.94% to $652000.0 in 2022, then surged by 265.18% to $2.4 million in 2023, then plummeted by 95.51% to $107000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $107000.0 in Q2 2024, $2.4 million in Q2 2023, and $3.7 million in Q1 2023.